Trials / Completed
CompletedNCT00882999
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 245 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2127399 | Administered via Injection |
| DRUG | Placebo | Administered via Injection |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2011-02-01
- Completion
- 2012-06-01
- First posted
- 2009-04-17
- Last updated
- 2018-11-15
- Results posted
- 2018-11-15
Locations
63 sites across 13 countries: United States, Bulgaria, Czechia, France, Germany, Hungary, Israel, Poland, Romania, Russia, Serbia, Slovakia, Ukraine
Source: ClinicalTrials.gov record NCT00882999. Inclusion in this directory is not an endorsement.